RxPatient Engagement App Automates Pharmacy Workflows, Designed to Strengthen Patient Engagement and Increase Pharmacist Productivity
Houston, Texas — March 7, 2022 — MarkeTouch Media, a leading healthcare technology company, which recently was combined with pharmacy technology provider EnlivenHealth®, today announced that RxPatient Engagement, its suite of patient engagement solutions, is now available in the Epic App Orchard marketplace. With integration of the RxPatient Engagement app, pharmacies can now access the entire suite of communication and clinical solutions from MarkeTouch Media, without ever having to leave their Epic pharmacy workflow.
RxPatient Engagement from MarkeTouch Media is a HIPAA-, ADA-, and TCPA-compliant solution that automates time-consuming pharmacy tasks and is intended to free up pharmacists to practice at the top of their license and focus on patient care. Supporting outbound SMS/text and voice notifications, inbound Interactive Voice Response (IVR), web, mobile, and clinical solutions, RxPatient Engagement leverages MarkeTouch Media’s patented processes1 to integrate with Epic. The result is that patients can choose how the pharmacy communicates with them. All RxPatient Engagement solutions are hosted, so there is no hardware or software required on-site.
“We are truly excited to be launching RxPatient Engagement in the Epic App Orchard,” said Lyle Green, vice president of sales for MarkeTouch Media. “The RxPatient Engagement app enables pharmacies to access and utilize the latest IVR, automated notifications, web and mobile technologies that are providing results for our 9,000+ partner pharmacies. Now that we are part of EnlivenHealth, we are looking to bring the RxPatient Engagement app capabilities to a growing network of pharmacy partners.”
For more information, visit RxPatient Engagement in the App Orchard. Epic and App Orchard are trademarks of Epic Systems Corporation.
About MarkeTouch Media
MarkeTouch Media (now a part of EnlivenHealth®) is a healthcare technology company committed to excellence in patient engagement. As a pioneer in automated outbound notifications in the healthcare space, MarkeTouch proudly celebrates its 20th anniversary in 2022. MarkeTouch manages over 1 million patient interactions every single day. The MarkeTouch difference is our unique combination of healthcare experience, tenured associates, communication expertise, innovative solutions, proven scalability, and time-tested reliability. To learn more, visit Marketouchmedia.com.
EnlivenHealth builds advanced patient engagement, financial management and population health technology solutions that enable retail pharmacies and health plans to measurably improve the health of their patients and members, while ensuring the long-term health of their business. With the recent acquisitions of FDS Amplicare and MarkeTouch Media, EnlivenHealth now offers one of the industry’s most comprehensive suite of SaaS technology solutions that help retail pharmacies and health plans to transform and thrive in this new era of digital-driven healthcare. Currently, more than 50,000 retail pharmacies nationwide deploy EnlivenHealth/FDS Amplicare/MarkeTouch Media technology solutions. EnlivenHealth is a division of Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. To learn more, visit EnlivenHealth.co.
ENLIVENHEALTH is a registered trademark of Omnicell, Inc. or one of its subsidiaries.
Certain statements contained in this press release relate to the expected benefits and objectives regarding MarkeTouch Media’s products and services, including the RxPatient Engagement App (and any implied financial impact). These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties some of which are beyond our control. These risks and uncertainties include, among other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) unfavorable general economic and market conditions or reduction in demand for our solutions, (iv) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, and (v) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission, available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.